?>

U.S. Department of Defense Invests In Prostrate Cancer Treatment

The U.S. Department of Defense/Prostrate Cancer Research Program (DoD/PCRP) gave a grant of just over $1.5 million dollars to SRI International to support pre-clinical studies of the non-profit organization’s agents that might be able to develop into drugs to treat prostate cancer. This grant follows an earlier one that had led to some positive results utilizing plant products.

The U.S. defense budget contains a great deal of novel R&D efforts and a lot of funding. Congress has used it to fund breast and other cancer and disease prevention and treatment research. Obviously the military has a great deal invested in their human capital and medical treatment and this funding helps in those areas. SRI International is a spin-off of Stanford University specializing in sponsored research for government, businesses and foundations.

Share this:
Share this page via Email Share this page via Stumble Upon Share this page via Digg this Share this page via Facebook Share this page via Twitter

>